A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naïve patients with chronic hepatitis B
Journal
Liver international : official journal of the International Association for the Study of the Liver
Journal Volume
43
Journal Issue
1
Date Issued
2023-01
Author(s)
Yuen, Man-Fung
Chen, Chi-Yi
Jeng, Wen-Juei
Elkhashab, Magdy
Coffin, Carla S
Kim, Won
Greenbloom, Susan
Ramji, Alnoor
Lim, Young S
Kim, Yoon J
Fung, Scott K
Kim, Dong J
Jang, Jeong-Won
Lee, Kwan Sik
Iyer, Radhakrishnan P
Macfarlane, Chelsea
Jackson, Kathy
Locarnini, Stephen A
Chan, Henry L Y
Afdhal, Nezam H
Abstract
Novel agents acting against hepatitis B virus (HBV) are needed to improve HBsAg seroclearance or termed as 'functional cure'. Inarigivir (retinoic acid-inducible gene I agonist) has immunomodulatory and direct antiviral actions against HBV. We aimed to determine the safety and efficacy of Inarigivir for the treatment of HBV infection.
Subjects
HBV DNA suppression; HBsAg level; Inarigivir; retinoic acid-inducible gene 1; tenofovir
Type
journal article